Trial · NCT03100344
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | From Baseline to Week 24 | All participants in intent-to-treat (ITT) population who received at least one dose of study drug. | percentage change | MEAN |
| SECONDARY | Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | Week 24 | ITT population: All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | From Week 1 to Week 24 | ITT population: All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24 | Baseline, Week 24 | ITT population: All randomized participants. | Percentage change | MEAN |
| SECONDARY | Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 24 | Baseline, Week 24 | ITT population: All randomized participants. | units on a scale | MEAN |
| SECONDARY | Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24 | Baseline, Week 24 | ITT population: All randomized participants. | Percentage change | MEAN |
| SECONDARY | Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) at Week 24 | Baseline, Week 24 | ITT population: All randomized participants. | units on a scale | MEAN |
| SECONDARY | Number of Participants Achieving Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) at Each Timepoint up to Week 24 | From Week 1 to Week 24 | ITT population: All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Eczema Area and Severity Index (EASI)-50 (Defined as Achieving 50% Reduction From Baseline in EASI Score) at Each Visit up to Week 24 | From Week 1 to Week 24 | ITT Population:All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Eczema Area and Severity Index (EASI)-75 (Defined as Achieving 75% Reduction From Baseline in EASI Score) at Each Visit up to Week 24 | From Week 1 to Week 24 | ITT Population: All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Eczema Area and Severity Index (EASI)-90 (Defined as Achieving 90% Reduction From Baseline in EASI Score) at Each Visit up to Week 24 | From Week 1 to Week 24 | ITT Population: All randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Achieving Investigator Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) and a Reduction of ≥2 Points at Each Visit up to Week 24 | Week 1 to Week 24 | All participants in ITT population who received at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Each Visit up to Week 24 | From Baseline to Week 24 | ITT population: All randomized participants. | Percentage of change | MEAN |
| SECONDARY | Percentage Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24 | At baseline and Week 24 | ITT population: All randomized participants. | percentage of change | MEAN |
| SECONDARY | Number of Participants With Adverse Events | From screening to Follow-up visit (Week 32)/Early termination visit | Safety population: The safety population comprised all subjects in ITT population who received at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24 | Baseline to Week 24 | ITT population: All randomized participants. Number of participants in this analysis | units on a scale | MEAN |
| SECONDARY | Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24 | Baseline to Week 24 | ITT population: All randomized participants. Number of participants in this analysis | units on a scale | MEAN |
| SECONDARY | Percentage Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale (NRS) at Each Visit up to Week 24 | Baseline to Week 24 | ITT population: All randomized participants. Number of participants in this analysis | Percentage of change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03100344/outcomes